Education
About Us
Working with TipRanks
Follow Us
InnoCare Pharma Ltd. (HK:9969)
:9969
RESEARCH TOOLSreports
Total Valuation
InnoCare Pharma Ltd. has a market cap or net worth of HK$15.71B. The enterprise value is HK$4.71B.
Market CapHK$15.71B
Enterprise ValueHK$4.71B
Share Statistics
InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,496,284,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
InnoCare Pharma Ltd.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee678.18K
Profits Per Employee-591.56K
Employee Count1,089
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of InnoCare Pharma Ltd. is ―. InnoCare Pharma Ltd.’s PEG ratio is ―.
PE Ratio―
PS Ratio12.59
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, InnoCare Pharma Ltd. had revenue of 738.54M and earned -631.26M in profits. Earnings per share was -0.37.
Revenue738.54M
Gross Profit610.10M
Operating Income-651.15M
Pretax Income-644.21M
Net Income-631.26M
EBITDA-516.55M
Earnings Per Share (EPS)-0.37
Cash Flow
In the last 12 months, operating cash flow was -501.88M and capital expenditures -29.13M, giving a free cash flow of ― billion.
Operating Cash Flow-501.88M
Free Cash Flow―
Free Cash Flow per Share0.00
Dividends & Yields
InnoCare Pharma Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.17
52-Week Price Change142.49%
50-Day Moving Average8.35
200-Day Moving Average6.38
Relative Strength Index (RSI)67.50
Average Volume (3m)10.32M
Important Dates
InnoCare Pharma Ltd. upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
InnoCare Pharma Ltd. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, InnoCare Pharma Ltd. has paid 1.43M in taxes.
Income Tax1.43M
Effective Tax Rate―
Enterprise Valuation
InnoCare Pharma Ltd. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
InnoCare Pharma Ltd. has HK$7.30B in cash and marketable securities with ¥1.03B in debt, giving a net cash position of -HK$5.91B billion.
Cash & Marketable SecuritiesHK$7.30B
Total Debt¥1.03B
Net Cash-HK$5.91B
Net Cash Per Share-HK$3.95
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for InnoCare Pharma Ltd. is HK$9.84, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$9.84
Price Target Upside11.44% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast33.63%
EPS Growth Forecast31.50%